Stock Analysis
- Denmark
- /
- Medical Equipment
- /
- CPSE:VIRO
ViroGates Reports Full Year 2023 Earnings
ViroGates (CPH:VIRO) Full Year 2023 Results
Key Financial Results
- Revenue: kr.6.99m (down 54% from FY 2022).
- Net loss: kr.12.1m (loss widened by 25% from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
ViroGates shares are down 2.3% from a week ago.
Risk Analysis
Be aware that ViroGates is showing 4 warning signs in our investment analysis and 3 of those are potentially serious...
Valuation is complex, but we're helping make it simple.
Find out whether ViroGates is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Simply Wall St
About CPSE:VIRO
ViroGates
ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector.
Excellent balance sheet with weak fundamentals.